Clovis Oncology Inc (CLVS) 2019年年度报告「NASDAQ」.pdf

《Clovis Oncology Inc (CLVS) 2019年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Clovis Oncology Inc (CLVS) 2019年年度报告「NASDAQ」.pdf（139页珍藏版）》请在三个皮匠报告上搜索。

1、TableofContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934.For the fiscal year ended December 31,2019.TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF

2、 1934.For the transition period from to .Commission file number:001-35347Clovis Oncology,Inc.(Exact name of Registrant as specified in its charter)Delaware90-0475355(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)5500 Flatiron Parkway,Suite 100Boulder,C

3、olorado80301(Address of principal executive offices)(Zip Code)(303)625-5000(Registrants telephone number,including area code)Not Applicable(Former name,former address and former fiscal year,if changed since last report)SecuritiesregisteredpursuanttoSection12(b)oftheActTitleofEachClassTradingSymbol(s

4、)NameofeachexchangeonwhichregisteredCommonStockparValue$0.001pershareCLVSTheNASDAQGlobalSelectMarketIndicatebycheckmarkiftheregistrantisawell-knownseasonedissuer,asdefinedinRule405oftheSecuritiesAct.YesNoIndicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttoSection13orSection15(d)oft

5、heAct.YesNoIndicatebycheckmarkwhethertheregistrant(1)hasfiledallreportsrequiredtobefiledbySection13or15(d)oftheSecuritiesExchangeActof1934duringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtofilesuchreports),and(2)hasbeensubjecttosuchfilingrequirementsforthepast90days.YesNo

6、IndicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryInteractiveDataFilerequiredtobesubmittedpursuanttoRule405ofRegulationS-T(232.405)ofthischapter)duringthepreceding12months(orforsuchshorterperiodthattheregistrantwasrequiredtosubmitsuchfiles).YesNoIndicatebycheckmarkwhethertheregis